Research Evidence / Overview of Studies for Ocaliva
Evidence for Use in Primary Biliary Cholangitis (PBC)
The medicine obeticholic acid was evaluated in research involving adults with Primary Biliary Cholangitis (PBC), a condition that is associated with acute or disruptive episodes. The core research includes short-term, placebo-controlled Randomized Controlled Trials (RCTs) cited by regulatory authorities, where patients were randomly assigned to receive either obeticholic acid or a placebo (a pill with no active medicine) for a defined period. These trials included adults whose condition was not responding adequately to the standard first-line medication, ursodeoxycholic acid (UDCA), and patients who were unable to tolerate UDCA.
The primary focus of these initial studies was to examine measurements of physiological strain or stress using short-term biochemical measures, known as surrogate endpoints. Researchers specifically measured changes in liver enzyme levels, such as Alkaline Phosphatase (ALP) and Total Bilirubin. The studies examined whether obeticholic acid was observed to contribute to reaching a specific target level for these markers over a one-year follow-up period. Studies reported measurements where a higher proportion of patients receiving obeticholic acid met the predefined criteria for the biochemical target compared to those who received the placebo.
Studying the Use with UDCA vs. Monotherapy
The research was conducted to explore the use of obeticholic acid in two ways. It was studied for use in combination with UDCA for patients whose PBC remained active despite UDCA treatment. It was also evaluated in patients who could not take UDCA, known as monotherapy (using the drug alone). The studies were designed to monitor whether the medicine's use resulted in changes in the short-term biochemical markers in both clinical situations. This research provides insight into the patterns related to the underlying liver process.
Focus of Clinical Trials: Outcomes Examined
Initial research primarily monitored the surrogate endpoints, which are changes in laboratory values that research highlights changes measured during the study period. These short-term measurements were monitored for changes in ALP. Surrogate markers are used as endpoints, but they do not confirm long-term clinical benefits.
To gain insight into the long-term impact, researchers also included assessments of patient-reported outcomes. These included assessments of patient-reported outcomes such as changes in pruritus (itching) and fatigue. Researchers applied in studies examining patient-reported experiences of these outcomes related to physical discomfort often present in this condition. While the studies recorded how these symptoms evolved in the observed populations, the main regulatory focus remained on the changes in the biochemical markers.
Long-Term Studies and Follow-up Data
Because the initial evaluation was based on surrogate markers, regulators required Confirmatory Post-Marketing Trials to track patients over an extended duration. These studies were studied for a composite outcome that included major clinical events: death, liver transplant, and hepatic decompensation (severe liver failure). These longer-term trials, which extended for several years in some cohorts, aimed to provide data that contributes to the broader evidence landscape regarding whether the changes seen in the short-term lab markers correspond to major clinical events (death, transplant, decompensation).
Data for long-term outcomes are not fully established. The required confirmatory trials tracking clinical events did not meet their primary endpoint of demonstrating a significant difference in the composite of death, liver transplant, or hepatic decompensation versus placebo in the overall population studied. Furthermore, the design of some long-term studies was complicated by factors such as crossover from the placebo to the active treatment, which introduced confounding factors in the research.
Research in Specific Patient Groups
The main clinical trials included various adult populations. However, data for certain groups remain insufficient. For instance, while some older adults were included, the evidence exploring how the medication performs specifically in patients over the age of 65 is limited.
Research also was evaluated in patients with different stages of underlying liver scarring. Studies were monitored in patients with compensated cirrhosis (a less advanced stage of scarring). However, data for certain groups remain insufficient, particularly for patients with more advanced stages of the disease, such as those with decompensated cirrhosis.
Main Evidence Gaps and Areas of Uncertainty
A central point of discussion in the research is the continued reliance on surrogate markers for initial evidence. Research highlights what is known — and what is still uncertain: the original evidence was based on a laboratory change, and long-term effects are not fully established by the subsequent clinical trials.
The fact that the required confirmatory trials tracking major clinical events did not meet their primary goal indicates that long-term clinical confirmation is still pending regarding the medicine's role in the prevention of death or liver transplant over many years. Therefore, while research provides insight into short-term changes, follow-up durations were limited in providing a definitive long-term picture, and the findings were mixed when assessing the most important clinical events.
